DAK HEALTH has floated a tender for Conclusion of a Non-Exclusive Discount Agreement in Accordance with Section 130A Paragraph 8 Sgb V for the Active Ingredient Natalizumab (Exclusively in the Dafo Injection Solution, Atc L04aa23 (Obo) for the Period 09/01/24 - 08/31/26. The project location is Germany and the tender is closing on 05 Jul 2026. The tender notice number is -, while the TOT Ref Number is 104259175.
Bidders can have further information about the Tender and can request the complete Tender document by Registering on the site.
Procurement Summary
Country : Germany
Summary : Conclusion of a Non-Exclusive Discount Agreement in Accordance with Section 130A Paragraph 8 Sgb V for the Active Ingredient Natalizumab (Exclusively in the Dafo Injection Solution, Atc L04aa23 (Obo) for the Period 09/01/24 - 08/31/26
Sign in with Google